ReviewWorld journal of gastroenterology2014
Therapeutic options for the management of pancreatic cancer.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.Scientific reports · 2015Pooled it
- Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa.Journal of translational medicine · 2021Trial
- Autophagy: a novel target in order to overcome drug resistance in pancreatic adenocarcinoma.Open biology · 2025Review
- Regulation of ubiquitin-proteasome system and its relative pathways in pancreatic adenocarcinoma.BioImpacts : BI · 2025Review
- Delta-Radiomics Approach Using Contrast-Enhanced and Noncontrast-Enhanced Computed Tomography Images for Predicting Distant Metastasis in Patients With Borderline Resectable Pancreatic Carcinoma.Advances in radiation oncology · 2025Article
- Investigation of interfractional range variation owing to anatomical changes with beam directions based on water equivalent thickness in proton therapy for pancreatic cancer.Journal of radiation research · 2024Article
- Irreversible electroporation promotes a pro-inflammatory tumor microenvironment and anti-tumor immunity in a mouse pancreatic cancer model.Frontiers in immunology · 2024Article
- Irreversible Electroporation in Pancreatic Cancer-An Evolving Experimental and Clinical Method.International journal of molecular sciences · 2023Review
- Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.BMC cancer · 2022Article
- Preoperative Risk Score for Early Mortality After Up-Front Pancreatic Cancer Surgery: A Nationwide Cohort Study.World journal of surgery · 2022Article
- Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells.Biomedicines · 2021Article
- Apamin-Conjugated Alendronate Sodium Nanocomplex for Management of Pancreatic Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review.Cell & bioscience · 2021Review
- Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: A survival, mortality and morbidity systematic review.Oncology letters · 2021Article
- Preoperative prediction of pathological grade in pancreatic ductal adenocarcinoma based onEJNMMI research · 2021Article
- Article
- Mitochondrial-Associated Protein LRPPRC is Related With Poor Prognosis Potentially and Exerts as an OncogeneFrontiers in genetics · 2021Article
- The Intricate Metabolism of Pancreatic Cancers.Advances in experimental medicine and biology · 2021Article
- KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target.Annals of translational medicine · 2020Article
- In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination.Journal for immunotherapy of cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its initial characterization, pancreatic ductal adenocarcinoma has remained one of the most devastating and difficult cancers to treat. Pancreatic cancer is the fourth leading cause of death in the United States, resulting in an estimated 38460 deaths annually. With few screening tools available to detect this disease at an early stage, 94% of patients will die within five years of diagnosis. Despite decades of research that have led to a better understanding of the molecular and cellular signaling pathways in pancreatic cancer cells, few effective therapies have been developed to target these pathways. Other treatment options have included more sophisticated pancreatic cancer surgeries and combination therapies. While outcomes have improved modestly for these patients, more effective treatments are desperately needed. One of the greatest challenges in the future of treating this malignancy will be to develop therapies that target the tumor microenvironment and surrounding pancreatic cancer stem cells in addition to pancreatic cancer cells. Recent advances in targeting pancreatic stellate cells and the stroma have encouraged researchers to shift their focus to the role of desmoplasia in pancreatic cancer pathobiology in the hopes of developing newer-generation therapies. By combining novel agents with current cytotoxic chemotherapies and radiation therapy and personalizing them to each patient based on specific biomarkers, the goal of prolonging a patient's life could be achieved. Here we review the most effective therapies that have been used for the treatment of pancreatic cancer and discuss the future potential of therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.